Skip to main content

Entera Bio Ltd.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

ENTX$3.25+3.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Changes in Shareholders' Equity

(U.S. dollars in thousands, except share and per share data)

Ordinary shares
Number of shares issued · Amounts · Additional paid-in capital · Accumulated other Comprehensive income · Accumulated deficit · Total
BALANCE AT JANUARY 1, 202435,476,3411114,73041(104,386)10,386
Net loss----(9,541)(9,541)
Exercise of warrants to ordinary shares89,820*90--90
Exercise of options to ordinary shares733,704*749--749
Issuance of ordinary shares under the ATM program, net of issuance costs2,236,126*3,840--3,840
Vested restricted share units301,229*(*)---
Share-based compensation--2,556--2,556
BALANCE AT DECEMBER 31, 202438,837,2201121,96541(113,927)8,080
Net loss----(11,439)(11,439)
Exercise of warrants to ordinary shares546,028*508--508
Exercise of options to ordinary shares26,448*20--20
Issuance of ordinary shares under the ATM program, net of issuance costs2,731,574*6,067--6,067
Issuance of ordinary shares under collaboration agreement, net3,685,226*7,115--7,115
Vested restricted share units352,134*(*)---
Share-based compensation--2,750--2,750
BALANCE AT DECEMBER 31, 202546,178,6301138,42541(125,366)13,101
  • Represents an amount less than one thousand U.S. dollars.

The accompanying notes are an integral part of these consolidated financial statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.